Affiliation:
1. Novartis Pharma AG, WKL-136.6.24, Postfach, CH-4002, Basel, Switzerland.
Abstract
Dr Jürg Zimmermann is the inventor of the drug imatinib (Gleevec®, Glivec®), which entered the market in 2001 and revolutionized the treatment of chronic myelogenous leukemia. He talks to Future Medicinal Chemistry about his career as a medicinal chemist, current issues in pharmaceutical R&D and his experiences of developing Gleevec, the first protein kinase to get onto market.
Subject
Drug Discovery,Pharmacology,Molecular Medicine
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献